RVL Pharmaceuticals PLC Investor Relations Material
Latest events
Q2 2023
RVL Pharmaceuticals PLC
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from RVL Pharmaceuticals PLC
Access all reports
RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals plc, is a specialty pharmaceutical company. The Company focuses on the development and commercialization of proprietary products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States